Respiratory Syncytial Virus – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of respiratory syncytial virus (RSV) infection comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report both the incidence and prevalence of RSV infection for each country as well as annualized case counts projected to the national population.

Clarivate Epidemiology’s RSV forecast will answer the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, together with the launch of the RSV vaccine affect the epidemiology of RSV over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following RSV subpopulations:

  • Live births by gestational age status.
  • Pediatric inpatients by risk group status.
  • Pediatric outpatients by risk group status.
  • Inpatients aged 0-4 years.
  • Outpatients aged 0-4 years.
  • Singleton pregnancy status.

Note: Coverage may vary by country.

launch Related Market Assessment Reports